Chronic Obstructive Pulmonary Disease (COPD) Drugs Market In China Will Reach At A CAGR Of 15.56% Between The Period 2016 – 2020

Researchmoz added Most up-to-date research on “Chronic Obstructive Pulmonary Disease (COPD) Drugs Market In China Will Reach At A CAGR Of 15.56% Between The Period 2016 – 2020” to its huge collection of research reports.

Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized by diffculty breathing. The exact etiology of COPD is not understood, but most cases are caused due to genetic factors and by inhaling pollutants, including smoke, fumes, and chemicals. As the disease develops, the symptoms tend to get worse and damages the lungs. The disease cannot be cured, and can only be managed and treated.

The COPD drugs market in China is under penetrated. It is dominated by fixed dose combinations of LABA/ICS. Air pollution is the major contributing factor for the growing prevalence of the disease. Nearly 10% of the population in the region who are over the age of 40 years has COPD. The disease is expected to become one of the leading causes of death in the country by 2020. Lack of awareness about the disease and its treatment options affects the growth of the market in this region.

Technavios analysts forecast the chronic obstructive pulmonary disease drugs market in China to grow at a CAGR of 15.56% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the chronic obstructive pulmonary disease drugs market in China for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the total consumption of the chronic obstructive pulmonary disease drugs globally. The report does not include revenue generated from the aftermarket service of the product.

The market is divided into the following segments based on drug class:
Bronchodilators
Phosphodiesterase-4 (PDE-4) inhibitors
Steroids
Combination therapies

Technavio’s report, Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=741902

Key vendors
AstraZeneca
Boehringer Ingelheim
GSK
Merck
Novartis
Other prominent vendors
Ache Laboratorios Farmaceuticos
Almirall
Aquinox Pharmaceuticals
Ario Pharma
BioMarck Pharmaceuticals
Gilead Sciences
Mereo BioPharma Group
Mylan
Orion
Pearl Therapeutics
Prosonix
Teva Pharmaceutical Industry
Theravance Biopharma
Theron Pharmaceuticals
Verona Pharma
Xention
ZAI Lab

Market driver
Increase in environmental pollution
For a full, detailed list, view our report

Market challenge
Low diagnosis rate
For a full, detailed list, view our report

Market trend
Increased focus on combination therapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Browse More Details @ http://www.researchmoz.us/copd-drugs-market-in-china-2016-2020-report.html

Designed by CyFocus.com
Powered by CyFocus.net
%d bloggers like this: